Back to news and events

Evogene Prices Its Initial Public Offering in the United States

The offering of 5 million ordinary shares prices at US$14.75 per share
Rehovot, Israel, November 21, 2013 – Evogene Ltd. (TASE: EVGN) today announced the pricing of its initial public offering in the U.S. of 5 million ordinary shares at a price of US$14.75 per share. In connection with the offering, Evogene has granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the same price per share. As part of the offering, one of the company’s shareholders, Monsanto Company, has agreed to purchase 813,560 ordinary shares at the initial public offering price, amounting to approximately US$12 million.
The shares are expected to begin trading on the New York Stock Exchange under the symbol “EVGN” on November 21, 2013. The offering is expected to close on November 26, 2013.
Credit Suisse Securities and Deutsche Bank Securities are acting as joint book-running managers for the offering, and Oppenheimer & Co. and Piper Jaffray & Co. are acting as comanagers.
This offering is being made solely by means of a prospectus, copies of which may be obtained by contacting: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY, 10010, telephone: +1 (800) 221-1037, e-mail:; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, telephone: +1 (800) 503-4611, email:
A registration statement relating to the initial public offering has been filed with and declared effective by the United States Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Evogene Ltd.
Evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and abiotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. Evogene’s headquarters are located in Rehovot, Israel and the Company is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN).
Karen Mazor
Director, Public and Investor Relations
T: +972 54 22 88 039